EU and US could reach trade deal this weekend - Reuters
Venus Concept Inc. (NASDAQ:VERO), a medical device company with a current market capitalization of $2.03 million, announced on Monday that it has entered into several agreements to extend the maturity dates of its various debt instruments. The amendments, which include extensions of the company’s Main Street Loan Agreement and Secured Subordinated Convertible Notes, push the maturity dates from December 2025 to December 2026. According to InvestingPro data, the company operates with a significant debt burden, with a debt-to-equity ratio of 3.79x.
The company also implemented a 1-for-11 reverse stock split, effective as of 5:00 p.m. Eastern Time on Sunday, following stockholder approval and a Board decision from the February 14, 2025 Special Meeting. This reverse stock split is anticipated to begin trading on an adjusted basis as the market opens today. The stock has faced significant challenges, with InvestingPro data showing a -66.35% return over the past year and a concerning financial health score of 1.64, labeled as "WEAK." For deeper insights into VERO’s valuation and future prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
The agreements, reached on February 28, 2025, provide Venus Concept with financial flexibility by extending the maturity date of its Main Street Loan Agreement from December 8, 2025, to December 8, 2026. Additionally, the company secured waivers for certain liquidity requirements and permission to apply a March 8, 2025, interest payment to the outstanding principal balance of each note.
Simultaneously, Venus Concept amended its secured convertible notes with Madryn Health Partners and EW Healthcare Partners, extending their maturity dates by one year to December 9, 2026. Moreover, a Twelfth Bridge Loan Amendment was signed to prolong the Bridge Loan’s maturity from February 28, 2025, to March 31, 2025.
The reverse stock split was executed to reduce the number of issued and outstanding shares of common stock, with every 11 shares being reclassified into one new share. This action does not change any rights or preferences of the common stock.
No fractional shares were issued as a result of the reverse stock split. Instead, fractional shares were rounded up to the nearest whole share. The reverse stock split is not expected to have a significant effect on ownership percentages due to the rounding up of fractional shares.
The adjustments to the debt instruments and the reverse stock split are strategic moves by Venus Concept to manage its capital structure and comply with its financial obligations, particularly important given the company’s negative EBITDA of -$24.15 million in the last twelve months. This news is based on a press release statement and documents filed with the SEC. InvestingPro subscribers have access to 13 additional key insights about VERO’s financial position and market performance, helping investors make more informed decisions.
In other recent news, Venus Concept Inc. has secured an additional $2.3 million in financing as part of its ongoing arrangement with Madryn Health Partners, with $2 million already disbursed. This financing will be used for general working capital purposes. The company also announced a reshuffle in its senior management team, with Dr. Hemanth Varghese, President and COO, stepping down and new appointments made, including Kirk Gunhus as Chief Revenue Officer and Melissa Kang as Chief Product Officer. Meanwhile, Venus Concept has entered into a Consent Agreement with its lenders, providing financial flexibility by waiving certain liquidity requirements until February 28, 2025. This agreement also allows the company to allocate an upcoming cash interest payment directly to the outstanding principal balance. Additionally, the Eleventh Bridge Loan Amendment Agreement has increased the Delayed Draw Commitment to $11 million and extended the maturity date to February 28, 2025. These strategic financial moves indicate a level of confidence from lenders in Venus Concept’s financial management. Investors and stakeholders are closely observing these developments as the company navigates the competitive landscape of the medical technology industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.